# Jiangxi Qingfeng Pharmaceutical Co. Ltd. trials: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials with Jiangxi Qingfeng Pharmaceutical Co. Ltd. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Jiangxi Qingfeng Pharmaceutical Co. Ltd.: 32 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/jiangxi-qingfeng-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 4, 2026 | NCT07563634 | Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 3 | Completed | Epilepsy, Focal | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07563634) |
| January 1, 2025 | NCT06754865 | Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive... | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Observational | Not yet recruiting | Acute Exacerbation of Chronic Obstructive Pulmonary Disease | 1,140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06754865) |
| November 7, 2024 | NCT06678542 | Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 | Completed | Healthy Participants | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06678542) |
| October 16, 2024 | NCT06643156 | Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 | Completed | Influenza | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06643156) |
| August 28, 2024 | NCT06574503 | Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 3 | Recruiting | Influenza | 748 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06574503) |
| August 27, 2024 | NCT06573008 | Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 3 | Recruiting | Influenza, Human | 328 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06573008) |
| April 18, 2023 | NCT05814926 | GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 | Completed | Healthy Volunteers, Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05814926) |
| March 29, 2023 | NCT05789342 | A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy... | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 | Completed | Healthy Volunteers | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05789342) |
| July 26, 2022 | NCT05474755 | To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 3 | Completed | Influenza | 591 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05474755) |
| November 2, 2021 | NCT05103241 | A Phase I Mass Balance Study of \[14C\]GP681 in Healthy Chinese Male Volunteers | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 | Completed | Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05103241) |
| June 15, 2021 | NCT04926506 | Efficacy and Safety of Intramuscular Injection of Xiyanping Injection in the Treatment of Acute Bronchitis in Children | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Not applicable | Unknown | Acute Bronchitis in Children | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04926506) |
| May 18, 2021 | NCT04891653 | A Phase I Study of BR790 in Subjects With Advanced Solid Tumors | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 | Unknown | Advanced Solid Tumor | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04891653) |
| February 4, 2021 | NCT04737837 | A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Observational | Unknown | Epilepsy, Focal-Onset Seizure | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04737837) |
| February 3, 2021 | NCT04736758 | A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 2 | Completed | Influenza | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04736758) |
| January 28, 2021 | NCT04729764 | Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 | Completed | Influenza | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04729764) |
| September 21, 2020 | NCT04556539 | Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 2 | Unknown | Advanced Ovarian Cancer | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04556539) |
| September 21, 2020 | NCT04556292 | A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 2 | Unknown | Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04556292) |
| July 27, 2020 | NCT04486937 | SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1/2 | Unknown | Metastatic Castration Resistant Prostate Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04486937) |
| March 5, 2020 | NCT04296383 | Xiyanping Injection Combined With Azithromycin VS Azithromycin for Children With pneumoniaProtozoal Pneumonia | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Not applicable | Unknown | Mycoplasma Pneumoniae Pneumonia | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04296383) |
| March 4, 2020 | NCT04295551 | Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia... | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Not applicable | Unknown | COVID-19 | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04295551) |
| February 19, 2020 | NCT04275388 | Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Observational | Unknown | 2019 Novel Coronavirus Pneumonia | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04275388) |
| November 8, 2019 | NCT04158310 | Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Observational | Unknown | Community Acquired Pneumonia | 9,207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04158310) |
| June 3, 2019 | NCT03971383 | Phase Ⅱc Sutdy of Aolanti Weikang Tablets in FD PDS Patients | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 2 | Unknown | Functional Dyspepsia | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03971383) |
| May 13, 2019 | NCT03947411 | Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Not applicable | Unknown | Severe Influenza | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03947411) |
| August 22, 2018 | NCT03641794 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 | Unknown | Advanced Solid Tumors | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03641794) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 3 | 4 |
| Phase 4 | 4 |
| Not applicable | 5 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 18 |
| Completed | 11 |
| Recruiting | 2 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Influenza, Human | 7 |
| Bronchitis | 2 |
| Pneumonia, Mycoplasma | 1 |
| Epilepsies, Partial | 1 |
| COVID-19 | 1 |
| Community-Acquired Pneumonia | 1 |
| Hand, Foot and Mouth Disease | 1 |
| Epilepsy | 1 |
| Seizures | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Pipe suppliers in the United States](https://specstream.ai/data/businesses/pipe-suppliers/united-states)
- [Cosmetology schools in the United States](https://specstream.ai/data/businesses/cosmetology-schools/united-states)
- [Research institutes in the United States](https://specstream.ai/data/businesses/research-institutes/united-states)
- [Emergency and urgent care facilities in the United States](https://specstream.ai/data/businesses/emergency-and-urgent-care-facilities/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
